Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

SEPPI, KLAUS; RAY CHAUDHURI, K.; COELHO, MIGUEL; FOX, SUSAN H.; KATZENSCHLAGER, REGINA; PEREZ LLORET, SANTIAGO; WEINTRAUB, DANIEL; SAMPAIO, CRISTINA

MOVEMENT DISORDERS

WILEY-LISS, DIV JOHN WILEY & SONS INC

Lugar: New York; Año: 2019 vol. 34 p. 180 - 198

0885-3185

Objective: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).Background: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.Methods: Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported.Results: A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non-dementia-level cognitive impairment.Conclusions: The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 International Parkinson and Movement Disorder Society.